We examine whether the historical dogma of multiple myeloma being incurable still holds true. The genomic chaos and resulting resistance to apoptosis of myeloma, long considered an obstacle to cure, formed the basis of the Arkansas Total Therapy (TT) program. The TT approach employs all myeloma-active drugs up-front to target drug-resistant sub-clones during initial treatment to prevent later relapse. Long-term follow up of altogether 1202 patients enrolled (TT1: n=231, median follow up: 21yr; TT2: 668, median follow up: 12yr; TT3a: n=303, median follow up: 9yr) permitted investigation of whether progression-free survival (PFS) and complete response (CR) duration were consistent with curability, i.e. observation of plateaus in Kaplan-Meier plots for PFS and CR duration. In the subset of 627 patients with plasma cell gene expression profiling data, cure plateaus were apparent at 5 years in the 14% with highrisk myeloma compared to 10 years in the remainder with low-risk disease. A parametric model based on PFS and CR duration supported an increase in curability with successive trials. Thus, 10-yr PFS and CR estimates increased from 8.8%/17.9% in TT1 to 15.5%/28.2% in TT2's control arm to 25.1%/35.6% in TT2's thalidomide arm and to 32.9/48.8% in TT3a. Toward developing novel therapies, we recommend a concerted focus on patients with high-risk myeloma whose outcome has not been advanced.
Introduction
between the 2 risk groups ( Figure 5A -B), gains were apparent for CRD in low-risk but not in high-risk disease (Figure 5C-D) . Interestingly, PFS, CRD and TTP curves reached plateaus at approximately 5 years in high-risk CMM, as opposed to more than 10 years in low-risk CMM.
Several statistical models were used to analyze TT outcomes. Relative survival was calculated as the ratio of observed to expected survival, based on US population life tables matched for age and gender (44); the ratios were estimated at 1-year intervals, given survival to the beginning of that interval (Supplemental Figure 1) . A relative survival ratio of at least 1 means patient mortality does not exceed that of the general population. Although there is some variability in the estimates, especially for the later times, relative survival ratios approach 1 at 10-15 years for TT1, but this occurs earlier, at 5-10 years, for TT2+Thal and TT3a. A parametric mixture cure model (45) was used to estimate PFS and CRD for each protocol, overall and by GEP-70 risk from baseline, as well as from a 5 year landmark for all patients. The general idea behind the model is that there are two groups, those that are at risk for the event of interest and those that are not. The combined survival probability is represented as a mixture of the survival probabilities for these two groups. Mathematically, the model states that the PFS or CRD curve, S(t), is given by S(t) = p + (1 -p) S 1 (t), where p is the cured fraction (long-term progression-or relapse-free survivors), and S 1 (t) is the curve for the remaining fraction. In our models, S 1 (t) was assumed to follow a Weibull distribution.
The cure model fit the data well and provided cure-fraction estimates that increase with later protocols and when examined from baseline and a 5-year landmark (Supplemental Figure 2) . Plateaus for both PFS-and CRD-based cure fractions emerged at 10 years in low-risk CMM and at 5 years in high-risk CMM (Supplemental Figure 3) . Numeric data are presented for all patients in Table 1 (regardless of GEP risk). PFS-based cure-fraction estimates increased significantly with successive TT trials: 9% in TT1, 16% in TT2-Thal, 25% in TT2+Thal, and 33% in TT3a (p=0.04); CRDbased cure-fraction estimates were 18%, 28%, 36%, and 49%, respectively (p=0.17).
When a 5-year landmark was applied to exclude early myeloma-related events, PFSbased cure fraction estimates were 28% in TT1, 39% in TT2-Thal, 51% in TT2+Thal, For personal use only. on July 16, 2017. by guest www.bloodjournal.org From and 70% in TT3a (p<0.001); in this setting, CRD-based cure fraction estimates were 32%, 47%, 56%, and 75%, respectively (p=0.007).
Is minimal residual disease (MRD) negativity an essential element for cure?
We have applied a sensitive 8 color flow cytometric approach for the assessment of MRD (19, 28) . In contrast to published reports focusing measurements on a landmark of 100 days after transplant, we examined MRD status in >10yr progression-free survivors of TT1 and TT2 protocols. In TT1, 35 surviving patients of the original 231 have been followed for at least 17 years; 21 remain progression-free, and one each was MRD-and MRD+ among the 2 patients tested. In the case of TT2, all 258 currently surviving patients of initially 668 have been followed for at least 10 years. Of 175 patients remaining progression-free, MRD testing was performed in 83 patients along with reexamination of clinical CR status. qualified for CR of whom 64 proved to be MRD-negative; among 17 patients not in CR, 14 were deemed MRD-positive and 3 MRD-negative. Collectively, these data indicate that the majority of long-term CR patients also qualified for MRD-negativity. A minority of patients had discordant readings between CR and MRD designations, 4 CR's were MRD-positive and 3 MRD-negative patients did not fulfill clinical CR criteria. In light of persistence of MRI-defined focal lesions in clinical CR and MRD negativity, further refinements of "global" patient CR and MRD designations are anticipated.
While most investigators consider CR a prerequisite for long-term PFS and cure (46-52), we reported previously that PFS and OS were not compromised by lack of CR in patients with documented preceding AMM (53) and those with MGUS-like CMM based on GEP (54, 55). However, CR was crucial for long term PFS and OS in high risk CMM (56). We also addressed the importance of a critical duration of CR for PFS durability (57). Best outcomes were observed when CR was sustained beyond a 3-year landmark. Those failing to achieve CR but remaining progression-free during this time frame fared better than patients attaining and losing CR. With long-term follow up available in TT1 and TT2 trials, we examined the role of CR for long term prognosis from a 2-year landmark (Figure 6 ). While PFS was superior in patients remaining in CR For personal use only. on July 16, 2017. by guest www.bloodjournal.org From at 2 years, plateaus were also apparent among non-CR patients. Thus, while a critical early event in terms of the degree of tumor mass reduction, CR is not essential for longterm disease control in all cases.
In search of an early surrogate marker for cure in CMM It is widely recognized that MM cells engage the bone marrow micro-environment for their survival and expansion and, through these interactions with stroma, receive signals that are responsible for cell adhesion-mediated drug resistance (58). Additional data suggest that the progression from MGUS to AMM to CMM is mediated via a change in stromal cell behavior, possibly mediated via an angiogenic switch, the underlying mechanism of which is under investigation (59, 60). We, therefore, compared GEP signatures of whole bone marrow biopsies from healthy donors and from patients with MGUS, AMM and CMM in CR or at baseline prior to therapy (Figure 7) . A median 37-gene score was highest in CMM at baseline and decreased progressively in comparisons of AMM to MGUS to CR and normal donors ( Figure 7A) ; the 37-gene score had a wider spread in CR patients than in healthy volunteers. GEP data of bone marrow biopsies from patients who achieved and remained in CR were compared with those of age-and gender-matched healthy donors. Preliminary data indicate that normal-like GEP signatures can be achieved during CR and are associated with outcomes superior to those associated with MM-like signatures ( Figure 7B ).
Challenges and opportunities for developing novel curative trials in CMM
Most of our cured patients have CMM that is classified by the GEP70 model as low risk and have been followed for at least 10 years. A review of mature trials that used novel agents without or with transplantation shows that their follow-up times are not yet sufficient for cure plateaus to have emerged (61, 62 We suggest that melphalan-type therapy may target MM stem cells with aggressive clinical behavior and thus prevent or at least reduce late relapse, thus, induce longlasting benefits with cure potential but that non-genotoxic drugs may require chronic therapy. Several more years of follow-up will be required to answer this important question.
Our data show that for patients with high-risk CMM, novel therapies are needed.
Even with TT approaches, median PFS of these patients is only 2 years although a small cure fraction of approximately 15% does emerge at 5 years. Work is in progress to determine whether earlier disease progression in high-risk CMM may be linked to a lower depth of CR as judged by sensitive MRD detection strategies.
In reflecting on the failure of our TT approach to advance clinical outcomes in high-risk MM, we considered the role of "cytokine storms" ensuing after chemotherapy or autologous transplants for steady state normal hematopoiesis to be established. By exerting stimulatory effects also on MM cells, such cytokine release may contribute to MM survival and disease escape. Our recently published metronomic therapy using low doses of cytotoxic agents (doxorubicin, cisplatin) in combination with bortezomib, thalidomide, and dexamethasone was exquisitely devoid of bone marrow toxicity (64).
Extending treatment to 28 days, we offered such therapy to 10 transplant-ineligible newly diagnosed patients with high-risk CMM. Treatment was well tolerated and brought about CR in 5 patients at the conclusion of one cycle, lasting unmaintained for up to 8 months (unpublished). In light of poor outcomes in high-risk CMM, we are following 1-cycle CR patients closely to determine the length of benefit and especially whether "down-grading" from GEP-defined high-to low-risk can be demonstrated.
Exome sequencing revealed a prevalence of K-RAS, N-RAS, and BRAFF mutations especially in advanced CMM (9, 10, 32, 33) . Using the MEK inhibitor trametinib (65), we have shown impressive preliminary response and have followed several patients with extra-medullary MM for 8+ months without recurrence. Applying such targeted therapies upfront in high-risk CMM will reveal whether durable CR's can be attained or whether, due to ITH, relapses are inevitable. We are investigating For personal use only. on July 16, 2017. by guest www.bloodjournal.org From whether, due to cross-talk among MM sub-clones, the efficacy of targeted therapies may also favorably affect off-target sub-clones.
Conclusions
The data presented here allow us to conclude that CMM has finally joined the "club" of curable malignancies. The assessment of curability, at least in the context of melphalan-based auto-transplants, requires a minimum follow-up of 10 and more years.
Based on CRD at baseline and a 5-year landmark, TT3a effectuated cure farction estimated of almost 50% and 75%, respectively, pertaining to the majority of patients with GEP-defined low-risk MM. Among the 15% of patients with high-risk CMM, only 15% were estimated cured with an earlier plateau apparent at 5 years.
High CR rates comparable to those achieved with more toxic autotransplantsupported high-dose melphalan have recently been reported with the sole use of novelagent combinations. Whether these different therapeutic approaches result in equally durable CR, longer follow up is required. In the interim, we are concerned about prematurely abandoning transplants in favor of therapy solely based on novel agents. In light of the stagnant clinical outcomes in high-risk CMM, we strongly endorse novel agent trials specifically for patients with GEP-based high-risk CMM where readily interpretable outcome results would be available within 2 to 3 years. For low-risk CMM, the availability of surrogate endpoints for cure would enormously aid in designing clinical trials aimed at developing less toxic therapy. Such approaches would include individualized therapy content and duration, taking into consideration GEP-based molecular subgroups potentially benefiting from different novel agents. Thus, the MS molecular subgroup is no longer considered high-risk when bortezomib is included in its management (42). Candidate surrogate methods include flow cytometric analysis of MRD and GEP analysis of whole bone-marrow biopsies, the latter encompassing MM cells and the microenvironment. Results of either method can be complicated by MRIand PET-defined focal lesions or macro-focal growth patterns in many CMM patients, which can persist years after onset of clinical CR. Therefore, it may be necessary for standard iliac crest sampling to be complemented by focal lesion examinations.
Alternatively, using mi-RNA (66) or exosome analysis (67) of peripheral blood may 1 0 emerge as a more powerful and quantitative approach, based on the notion of metastatic trafficking of MM cells between bone marrow and extra-medullary sites (68).
Although ITH is widely appreciated as the major obstacle to cure, our data indicate curability in both low-and high-risk CMM when applying TT principles.
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Figure 7: Gene Expression Profiling of Bone Marrow Biopsy Material
Gene expression profiling of whole bone marrow biopsy material encompasses in both hematopoietic and bone marrow micro-environmental tissues. In the case of myeloma and precursor conditions, myeloma plasma cells co-exist in the biopsy material with normal hematopoietic and stromal elements. Marked differences in the 37-gene score were noted between CMM, AMM, MGUS, CR, and Normal Donors (A). Myeloma patients qualifying for complete response (CR) status and whose bone marrow biopsy becomes normal donor-like ("normalization") enjoy superior CR duration than their counterparts not qualifying for normalization. CR Duration according to "Normalization" of bone marrow biopsies of patients with MM was compared (B). 
